Validation of a recombinant based antibody ELISA for diagnosis of human and canine leishmaniasis.
In this study, a recombinant chimeric antigen (CA) ELISA was validated as a single test for both human and dog leishmaniasis. Serum panels included 327 human and 339 canine IFAT-positive and 1113 human and 1078 canine IFAT-negative samples. CA-ELISA was carried out using the same serum dilution, and labelled protein A as secondary reagent. Test performances were calculated using ROC analysis. For the human panel, the test showed diagnostic accuracy (DA) 0.974, specificity (Sp) 97.12%, sensitivity (Se) 91.44%, and concordance (K) 0.88. The dog panel showed DA 0.998, Sp 99.54%, Se 98.54%, and K 0.98. The proposed method is the best recombinant antigen-based ELISA, and can be used as IFAT substitute for mass screening.
Daprà
Franco
F
Department of Animal Production, Epidemiology and Ecology, Faculty of Veterinary Medicine, University of Torino, Via Leonardo da Vinci 44, 10095 Grugliasco (TO), Italy.
Scalone
Aldo
A
Mignone
Walter
W
Ferroglio
Ezio
E
Mannelli
Alessandro
A
Biglino
Alberto
A
Zanatta
Renato
R
Gradoni
Luigi
L
Rosati
Sergio
S
D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood*; D000953:Antigens, Protozoan / Q000276:immunology*; D004283:Dog Diseases / Q000175:diagnosis* / Q000276:immunology; D004285:Dogs; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods*; D006801:Humans; D007891:Leishmania / Q000276:immunology*; D007896:Leishmaniasis / Q000175:diagnosis* / Q000276:immunology / Q000662:veterinary*; D011993:Recombinant Fusion Proteins / Q000276:immunology; D012680:Sensitivity and Specificity
D000913:Antibodies, Protozoan; D000953:Antigens, Protozoan; D011993:Recombinant Fusion Proteins